Jeff Yass’s Pasithea Therapeutics KTTA Stock Holding History

Jeff Yass’s Portfolio KTTA Stock Details KTTA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-1,928	Closed	-$18.5K	–	12867
2023 Q3	$18.5K	Buy	+1,928	New	+$21.1K	﹤0.01%	11620
2023 Q2	–	Sell	-569	Closed	-$4.42K	–	12662
2023 Q1	$4.42K	Buy	+569	New	+$6.43K	﹤0.01%	12318

Other funds holding KTTA

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

Jeff Yass's KTTA Position: Q4 2023 in Review

Jeff Yass sold out of Pasithea Therapeutics (KTTA) in Q4 2023, closing a stake of 1,928 shares — an estimated $18.5K sold.

Jeff Yass first reported a position in KTTA in Q1 2023 and held it in 2 quarters. The position peaked at $18.5K in Q3 2023. 8 funds tracked by Wall St. Rank hold KTTA as of Q4 2023.

Jeff Yass reported no remaining Pasithea Therapeutics position as of Q4 2023 after selling out during the quarter.
Jeff Yass sold 1,928 Pasithea Therapeutics shares in Q4 2023, an estimated $18.5K.
Jeff Yass first reported a position in Pasithea Therapeutics in Q1 2023 and held it in 2 quarters.
Jeff Yass's Pasithea Therapeutics position peaked at $18.5K in Q3 2023.
8 funds tracked by Wall St. Rank held Pasithea Therapeutics as of Q4 2023.

Based on Susquehanna International Group's 13F filing for Q4 2023, filed 14 Feb 2024.